CagriSema Guide
Semaglutide + Cagrilintide: REDEFINE Phase 3 Data & Approval Timeline
CagriSema combines semaglutide (a GLP-1 agonist) with cagrilintide (an amylin analogue) into a single weekly injection. The REDEFINE Phase 3 program demonstrated substantial weight loss beyond what either compound achieves alone. This guide covers the mechanism, trial results, dosing, side-effect profile, and expected FDA timeline.
What Is Cagrisema?
CagriSema combines semaglutide, a GLP-1 receptor agonist, with cagrilintide, a long-acting amylin analog that has been studied for obesity. The combination is intended to target appetite and satiety through complementary pathways.
Phase 3 trials reported clinically meaningful weight loss and gastrointestinal adverse events that were mostly transient and mild to moderate. That makes the therapy promising, but also one that needs careful tolerability tracking.
Use Shotlee to log your own protocol data if you are following a comparable research or treatment plan under clinician supervision.
Mechanism Highlights
Targets GLP-1 signaling
Targets amylin signaling
May reduce appetite and food intake
May slow gastric emptying
Phase 3 trials showed greater weight loss than placebo
GI side effects were common in trials
CagriSema Snapshot
In a 68-week phase 3 trial in adults with overweight or obesity, cagrilintide-semaglutide reduced mean body weight by about 20.4% compared with 3.0% with placebo.
A separate phase 3 study in adults with overweight or obesity and type 2 diabetes also reported clinically relevant weight loss with the combination.
Use the page as a snapshot of the published evidence, not as a substitute for current prescribing information.
Trial Administration
Once-weekly subcutaneous dosing was used in phase 3 studies
Dose escalation schedules varied by protocol
Published trial regimens are not the same as an approved labeled dose
Track the exact regimen if you are comparing outcomes over time
Side Effects
Common in Trials
Nausea, vomiting, diarrhea, constipation, abdominal pain, and injection site reactions
Tolerability
GI adverse events were common but usually transient and mild to moderate in severity
Evidence Timeline
2025:
Phase 3 obesity trial reported substantial weight loss with cagrilintide-semaglutide
2025:
A companion diabetes population study also reported clinically relevant weight loss
Ongoing:
Additional analyses continue to refine the benefit-risk picture
Key Questions
What is CagriSema?
An investigational semaglutide + cagrilintide combination studied for obesity and related metabolic conditions.
How strong is the evidence?
Phase 3 data show clinically meaningful weight loss, but the exact benefit-risk balance depends on the final regimen and follow-up data.
What should I track?
Dose timing, GI symptoms, weight trend, and any changes in appetite or tolerability are the most useful protocol logs.
Is it the same as semaglutide alone?
No. The combination adds cagrilintide, an amylin analog, so the evidence and tolerability profile are not identical to semaglutide monotherapy.
Guide FAQs
CagriSema is an investigational combination of semaglutide and cagrilintide studied for obesity.
Yes. Shotlee supports tracking CagriSema doses, side effects, and health metrics. It is free to use.
References
Track Your Cagrisema Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.
🚀 Use Shotlee for Free